High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer.

Liao, Xiaohong; Liu, Chao; Ding, Zhenluo; Wang, Chen; He, Jing; Wu, Shugui

Liao, Xiaohong; Liu, Chao; Ding, Zhenluo; Wang, Chen; He, Jing; Wu, Shugui.

Afiliación

Liao X; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
Liu C; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
Ding Z; Department of Breast Surgery, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
Wang C; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
He J; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.
Wu S; Department of Oncology, Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, China.

Medicine (Baltimore) ; 102(25): e34164, 2023 Jun 23.

Article en En | MEDLINE | ID: mdl-37352040

Asunto(s)

Neoplasias de la Mama; Neoplasias de la Mama Triple Negativas; Humanos; Femenino; Neoplasias de la Mama Triple Negativas/patología; Terapia Neoadyuvante/métodos; Neoplasias de la Mama/patología; Pronóstico; Linfocitos Infiltrantes de Tumor/metabolismo; Biomarcadores/metabolismo; Factores de Transcripción/metabolismo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Medicine (Baltimore) Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google